RT Journal Article SR Electronic T1 SETBP1 variants outside the degron disrupt DNA-binding and transcription independent of protein abundance to cause a heterogeneous neurodevelopmental disorder JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.03.04.22271462 DO 10.1101/2022.03.04.22271462 A1 Maggie MK Wong A1 Rosalie A Kampen A1 Ruth O Braden A1 Gökberk Alagöz A1 Michael S Hildebrand A1 Christopher Barnett A1 Meghan Barnett A1 Alfredo Brusco A1 Diana Carli A1 Bert BA de Vries A1 Alexander JM Dingemans A1 Frances Elmslie A1 Giovanni B Ferrero A1 Nadieh A Jansen A1 Ingrid MBH van de Laar A1 Alice Moroni A1 David Mowat A1 Lucinda Murray A1 Francesca Novara A1 Angela Peron A1 Ingrid E Scheffer A1 Fabio Sirchia A1 Samantha J Turner A1 Aglaia Vignoli A1 Arianna Vino A1 Sacha Weber A1 Wendy K Chung A1 Marion Gerard A1 Vanessa López-González A1 Elizabeth Palmer A1 Angela T Morgan A1 Bregje W van Bon A1 Simon E Fisher YR 2022 UL http://medrxiv.org/content/early/2022/03/08/2022.03.04.22271462.abstract AB Germline de novo SETBP1 variants cause clinically distinct and heterogeneous neurodevelopmental disorders. Heterozygous missense variants at a hotspot encoding a canonical degron lead to SETBP1 accumulation and Schinzel-Giedion syndrome (SGS), a rare severe developmental disorder involving multisystem malformations. Heterozygous loss-of-function variants result in SETBP1 haploinsufficiency disorder which is phenotypically much milder than SGS. Following an initial description of four individuals with atypical SGS carrying heterozygous missense variants adjacent to the degron, a few individual cases of variants outside the degron were reported. Due to the lack of systematic investigation of genotype-phenotype associations of different types of SETBP1 variants, and limited understanding of the roles of the gene in brain development, the extent of clinical heterogeneity and how this relates to underlying pathophysiological mechanisms remain elusive, imposing challenges for diagnosis and patient care. Here, we present a comprehensive investigation of the largest cohort to-date of individuals carrying SETBP1 missense variants outside the degron (n=18, including one in-frame deletion). We performed thorough clinical and speech phenotyping with functional follow-up using cellular assays and transcriptomics. Our findings suggest that such variants cause a clinically and functionally variable developmental syndrome, showing only partial overlaps with classical SGS and SETBP1 haploinsufficiency disorder, and primarily characterised by intellectual disability, epilepsy, speech and motor impairment. We provide evidence of loss-of-function pathophysiological mechanisms impairing ubiquitination, DNA-binding and transcription. In contrast to SGS and SETBP1 haploinsufficiency, these effects are independent of protein abundance. Overall, our study provides important novel insights into diagnosis, patient care and aetiology of SETBP1-related disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Max Planck Society (M.M.K.W., R.A.K., G.A., A.V., and S.E.F.). W.K.C was funded by SFARI and the JPB Foundation. M.S.H., I.E.S., and A.T.M. were funded by a National Health and Medical Research Council (NHMRC) Centre of Research Excellence Grant (1116976), an Australian Research Council (ARC) Discovery Project (DP120100285), an NHMRC Project Grant (1127144), and the March of Dimes Grant Scheme. M.S.H. was funded by an NHMRC Career Development Fellowship (1063799). I.E.S. was funded by an NHMRC Investigator Grant (1172897), an NHMRC Practitioner Fellowship (1006110), and NHMRC Development Grant (1153614). A.T.M. was funded by an NHMRC Investigator Grant (1195955), an NHMRC Practitioner Fellowship (1105008), and an NHMRC Development Grant (1153614). E.P. was supported by the National Health and Medical Research Council (GNT11149630), Australia and the research WGS was supported by NHMRC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen under number 2011/188 gave ethical approval for this work The Human Research Ethics Committee of The Royal Children's Hospital, Melbourne, Australia, approved study and testing on a research basis of proband 1 (Project 37353).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors